Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Hyaluronic acid (HA), an excellent biomaterial with unique bio properties, is currently one of the most interesting polymers for many biomedical and cosmetic applications. However, several of its potential benefits are limited as it is rapidly degraded by hyaluronidase enzymes. To improve the half-life and consequently increase performance, native HA has been modified through cross-linking reactions with a natural and biocompatible amino acid, Ornithine, to overcome the potential toxicity commonly associated with traditional linkers. 2-chloro-dimethoxy-1,3,5-triazine/4-methylmorpholine (CDMT/NMM) was used as an activating agent. The new product (HA–Orn) was extensively characterized to confirm the chemical modification, and rheological analysis showed a gel-like profile. In vitro degradation experiments showed an improved resistance profile against enzymatic digestions. Furthermore, in vitro cytotoxicity studies were performed on lung cell lines (Calu-3 and H441), which showed no cytotoxicity.

Details

Title
Design, Synthesis, Characterization, and In Vitro Evaluation of a New Cross-Linked Hyaluronic Acid for Pharmaceutical and Cosmetic Applications
Author
Sciabica, Sabrina 1 ; Tafuro, Giovanni 2 ; Semenzato, Alessandra 2   VIAFID ORCID Logo  ; Traini, Daniela 3   VIAFID ORCID Logo  ; Silva, Dina M 3 ; Larissa Gomes Dos Reis 3 ; Canilli, Luisa 4 ; Terno, Massimo 4 ; Durini, Elisa 1 ; Vertuani, Silvia 1 ; Baldisserotto, Anna 1   VIAFID ORCID Logo  ; Manfredini, Stefano 1   VIAFID ORCID Logo 

 Department of Life Sciences and Biotechnology, University of Ferrara, Via L. Borsari 46, 44121 Ferrara, Italy; [email protected] (S.S.); [email protected] (E.D.); [email protected] (S.M.) 
 Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy; [email protected] (G.T.); [email protected] (A.S.) 
 Macquarie Medical School, Department of Medical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University & Woolcock Institute of Medical Research, Sydney 2037, Australia; [email protected] (D.T.); [email protected] (D.M.S.); [email protected] (L.G.D.R.) 
 Istituto Ganassini S.p.A., Via Carlo Boncompagni, 63, 20139 Milano, Italy; [email protected] (L.C.); [email protected] (M.T.) 
First page
1672
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
19994923
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2584450113
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.